April 23, 2013
- Roche today announced changes to the management and set-up of its life-science business. The Applied Science Business Area will be dissolved and its portfolio of products integrated within Roche's other Diagnostics Business Areas. This will streamline decision-making and enhance technology flow from research use to the clinical setting.
- 30 September - 1 October 2013, Odense, Denmark.
Denmark will over the next ten years, spend € 5.5 billion on the construction of eight new super hospitals, including the new Odense University Hospital (OUH). Region Southern Denmark is therefore inviting international stakeholders from the public and private sector to meet and discuss how to ensure sustainable future health care solutions through innovative private and public partnerships. The congress "Hospital + Innovation...
- • In the Phase III clinical trial STARTVerso™1, up to 80% of patients treated with faldaprevir+ and PegIFN/RBV achieved viral cure (SVR12) • At both doses, 87 to 89% of patients met criteria to stop all treatment after 24 weeks and 86 to 89% of these patients went on to achieve SVR12 • Faldaprevir+ was well tolerated at both doses; at the lower dose side-effect related treatment discontinuation was similar to placebo - For media outside USA, UK and Canada only
April 22, 2013
- Researchers at Albert Einstein College of Medicine of Yeshiva University have developed a therapy for pancreatic cancer that uses Listeria bacteria to selectively infect tumor cells and deliver radioisotopes into them. The experimental treatment dramatically decreased the number of metastases (cancers that have spread to other parts of the body) in a mouse model of highly aggressive pancreatic cancer without harming healthy tissue.
- Children can get five to 10 colds each year, so it's not surprising that adults often turn to over-the-counter cough and cold medicines to relieve their little ones' symptoms. But a new University of Michigan poll shows that many are giving young kids medicines that they should not use.
- Concerns have been raised in the media about certain stem cell therapy treatments.
- AstraZeneca and BIND Therapeutics announced today that they have entered into a strategic collaboration to develop and commercialise an Accurin™, a targeted and programmable cancer nanomedicine from BIND’s Medicinal Nanoengineering platform, based on a molecularly targeted kinase inhibitor developed and owned by AstraZeneca.
- Unavoidable damage caused to the heart and lungs by radiotherapy treatment of tumours in the chest region can be limited by the administration of an ACE inhibitor, a drug commonly used in the treatment of cardiovascular disease, a group of Dutch researchers have found. Common cancers such as breast, oesophagus, lung, and Hodgkin's lymphoma are frequently treated with radiotherapy, but the radiation dose that can be given safely is limited by the sensitivity of the health lung tissue which is...
April 21, 2013
- A massive study analyzing gene expression data from 22 tumor types has identified multiple metabolic expression changes associated with cancer. The analysis, conducted by researchers at Columbia University Medical Center, also identified hundreds of potential drug targets that could cut off a tumor's fuel supply or interfere with its ability to synthesize essential building blocks.